Dr. Peri is currently the Branch Chief, for the Division of Pre-Marketing Assessment, in the Office of New Drug Quality Assessment. His responsibilities include the supervising work assignments and reviews of INDs, NDAs, Intercenter consults requests, and other Special Projects supporting ONDQA and the clinical divisions of Pulmonary, Allergy, Rheumatology, Analgesia, and Anesthetics products. He is also the FDA liaison for the USP's small molecules monograph development division and the coordinator of ONDQA Inhalation Focus Group. Dr. Peri obtained his Ph.D. in Medicinal Chemistry from the College of Pharmacy, University of Iowa. After research positions at the University of Maryland Baltimore County and Loyola University Chicago, he joined Abbott Laboratories as a scientist in the process research and development team. He joined the FDA in 1999.